Fig. S1.
(A) The indicated lymphoma cells (5 × 106) were implanted s.c. in NOD/SCID mice (n = 7), and mice were administered PG545 (i.p., 20 mg/kg, once weekly, starting 1 d after cell inoculation), or control vehicle (PBS; Con). At termination, tumors were removed, weighed, and embedded in paraffin for histological and immunohistochemical analyses. Shown are average (±SE) tumor weights (g). El-4 mouse lymphoma (B) and rat C6 glioma (C) cells (1 × 105) were inoculated s.c. into C57BL/6 (El-4) or SCID (C6) mice (n = 7), and mice were treated with PG545 (i.p., 20 mg/kg, once weekly) or control vehicle. At termination, tumor xenografts were harvested, weighed (Upper), and embedded in paraffin for histological examination. Portions of the untreated (red) and treated (green) tumors were lysed for determination of heparanase activity, along with a sample that exhibits high enzymatic activity (Pos, B, Lower). Note that El-4 and C6 cells and tumor xenografts lack heparanase activity, and that PG545 failed to inhibit the growth of these tumors.